Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate

Clinical and Experimental Rheumatology

Volumn 25, Issue 6, 2007, Pages 888-889

  Gwak, Geum Youn ^a   Koh, Kwang Cheol ^a   Kim, Hye Young ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Hepatitis B virus; Methotrexate; Reactivation; Rheumatoid arthritis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; IMMUNOGLOBULIN M; LAMIVUDINE; METHOTREXATE; PREDNISOLONE; VIRUS DNA;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BRAIN DISEASE; CASE REPORT; CLINICAL FEATURE; DEATH; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; HYPOALBUMINEMIA; IMMUNOCOMPROMISED PATIENT; LIVER FAILURE; LIVER FUNCTION TEST; LOW DRUG DOSE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RHEUMATOID ARTHRITIS; SEROLOGY; VIRUS REACTIVATION; VIRUS REPLICATION;

AGED; ARTHRITIS, RHEUMATOID; FATAL OUTCOME; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LAMIVUDINE; LIVER FAILURE; METHOTREXATE; VIRUS ACTIVATION;

EID: 38649110203     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. BALDINI C, DELLE SEDIE A, BOMBARDIERI S: From clinical trials to the bedside: How can we treat patients with rheumatoid arthritis and concurrent morbidities who are generally excluded from randomised controlled clinical trials? Clin Exp Rheumatol 2005; 23: 893-904.
2. LANG B, RIEGEL W, PETERS T, PETER HH: Low dose methotrexate therapy for rheumatoid arthritis complicated by pancytopenia and Pneumocystis carinii pneumonia. J Rheumatol 1991; 18: 1257-9.
3. LYON CC, THOMPSON D: Herpes zoster encephalomyelitis associated with low dose methotrexate for rheumatoid arthritis. J Rheumatol 1997; 24: 589-91.
4. FLOWERS MA, HEATHCOTE J, WANLESS IR et al.: Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990; 112: 381-2.
5. NARVAEZ J, RODRIGUEZ-MORENO J, MARTINEZ-AGUILA MD, CLAVAGUERA MT: Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol 1998; 25: 2037-8.
6. ITO S, NAKAZONO K, MURASAWA A et al.: Development of fulminant hepatitis B (pre-core variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001; 44: 339-42.
7. HAGIYAMA H, KUBOTA T, KOMANO Y, KUROSAKI M, WATANABE M, MIYASAKA N: Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol 2004; 22: 375-6.
8. HOOFNAGLE JH, DUSHEIKO GM, SCHAFER DF et al.: Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 1982; 96: 447-9.
9. YEO W, CHAN PKS, ZHONG S et al.: Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factors. J Med Virol 2000; 62: 299-307.
10. YEO W, LAM KC, ZEE B et al.: Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 2004; 15: 1661-6.
11. REHERMANN B, FERRARI C, PASQUINELLI C, CHISARI FV: The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996; 2: 1104-8.
12. LEUNG NWY, TAM JSL, LAU GTC, LEUNG TWT, LAU WY, LI AKC: Hepatitis B virus DNA in peripheral blood leucocytes - a comparison between hepatocellular carcinoma and other hepatitis B virus-related chronic liver diseases. Cancer 1994; 73: 1143-8.
13. WANDS JR, CHURA CM, ROLL FJ, MADDREY WC: Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975; 68: 105-12.
14. MEULEMAN P, LIBBRECHT L, WIELAND S et al.: Immune suppression uncovers endogenous cytopathic effects of the hepatitis B virus. J Virol 2006; 80: 2797-807.